Selective S1P1 Agonists for Autoimmune Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for multiple sclerosis and other autoimmune diseases lack selectivity and efficacy due to non-selective immunosuppressive agents, leading to tolerability issues and limited therapeutic windows.
Innovation Solution
Development of selective S1P1/Edg1 receptor agonists, such as oxadiazole compounds, which modulate S1P receptor signal transduction, offering improved pharmacological properties and selectivity over S1P3/Edg3 receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective immunosuppressive agents are used, then broad immunosuppressive activity is achieved, but selectivity and tolerability deteriorate
Solution Approach 1:
The invention segments the immunosuppressive activity by designing compounds that selectively target specific S1P receptor subtypes (S1P1, S1P2, S1P3) rather than all S1P receptors. This is achieved through molecular structure optimization to achieve subtype-selective binding, thereby providing immunosuppressive effects while reducing off-target toxicity associated with non-selective agents
Solution Approach 2:
The invention applies local quality by creating compounds with differentiated binding affinities for different S1P receptor subtypes. The molecular structures are designed to preferentially bind to specific receptor subtypes (e.g., S1P1 over S1P3) based on local structural features and interactions, enabling selective immunosuppression in specific tissue contexts while sparing others
2Reliability
If non-selective immunosuppressive agents are used, then immunosuppressive coverage is achieved, but therapeutic window deteriorates
Solution Approach 1:
The invention introduces dynamics by designing compounds with可调 (tunable) selectivity profiles for different S1P receptor subtypes. The molecular structures allow for dynamic adjustment of binding preferences based on disease state and tissue context, enabling optimization of therapeutic window by selecting appropriate compounds for specific clinical scenarios
Solution Approach 2:
The invention applies parameter changes by systematically varying molecular parameters (substituents, functional groups, stereochemistry) to modulate binding affinity and selectivity for different S1P receptor subtypes. This enables fine-tuning of the therapeutic window by adjusting the balance between immunosuppressive efficacy and side effect profile through structural modification
Data Source
AI summary
The invention relates to compounds of formula I: wherein R1, R2, Ra, Rb, W, Q and S have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.